Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer have?
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer has 2,094 citations in the OpenAlex counts ScholarIQ stores.
When was Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer published?
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer has 2015 year in the ScholarIQ index.
What is the open-access status of Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer?
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer has bronze oa status in the ScholarIQ index.
What is the DOI of Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer?
The DOI for Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer is on the source record.
What is the PMID of Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer?
The PMID for Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer is on the source record.
What is the OpenAlex record for Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer?
The OpenAlex for Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer is on the source record.